Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis

Abstract Activation of antigen-specific T-lymphocyte responses may be needed to cure disorders caused by chronic infection with low-risk human papillomavirus (lrHPV). Safe and effective adjuvant therapies for such disorders are needed. The safety and efficacy of a novel gorilla adenovirus vaccine ex...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Maxwell Y. Lee, Simon Metenou, Douglas E. Brough, Helen Sabzevari, Ke Bai, Caroline Jochems, Jeffrey Schlom, Clint T. Allen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/4ee4cb16ac8a46e2a8da230bdd87a086
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!